Renoprotective Effects of Telbivudine in Chronic Hepatitis B
Status:
Completed
Trial end date:
2018-05-31
Target enrollment:
Participant gender:
Summary
Renal impairment is common in patients with chronic hepatitis B infection. For those taking
nucleotide analogues, renal toxicity of adefovir disoproxil (ADV) and tenofovir disoproxil
fumarate (TDF) is a significant concern in chronic hepatitis B (CHB) patients. Early
observational clinical data suggested that telbivudine (LdT) might have renoprotective
effects. In this prospective study, consecutive CHB patients on combined lamivudine
(LAM)+ADV/TDF are switched to LdT+ADV/TDF at recruitment and are followed up for 24 months.
Estimated glomerular filtration rate (eGFR) is calculated with the Modification of Diet in
Renal Disease (MDRD) equation. The effects of LdT on cell viability and expression of kidney
injury or apoptotic biomarkers are investigated in cultured renal tubular epithelial cell
line HK-2.